Bacterial resistance to available antibiotics is becoming an increasing problem; methicillin-resistant Staphylococcus aureus (MRSA), which is broadly resistant to penicillins and cephalosporins, is a particular problem in hospital settings.
A recent report in the journal Science describes new compounds effective against MRSA. The compounds target FtsZ, a bacterial homologue of mammalian β-tubulin, which is essential for bacterial cell division. One of the compounds, PC190723, has been shown to have potent in vitro bactericidal activity against staphylococci, including MRSA, and also to cure mice infected with a lethal dose of MRSA.
The binding site for PC190723 has been mapped to a region of FtsZ that is analogous to the paclitaxel -binding site of tubulin. The activity of PC190723 further validates FtsZ as an antibacterial target, and provides the basis for optimisation to provide new treatments for MRSA.
Related posts:
- Never Mind the Colour – New Coating Kills MRSA on Contact Methicillin-resistant Staphylococcus aureus (MRSA) infections are a particular problem in hospitals and other healthcare environments. MRSA can survive on normal...
- Nanoparticles Effective against Brain Infection Brain infections such as bacterial meningitis and encephalitis can cause death or serious disability and are difficult to treat with...
- NO Place to Hide for Bacteria with Synthase Inhibitors Since the late 1980s, when nitric oxide (NO) was first shown to play a physiological role in mammals, this small...
- Progress in Targeting the Sliding Clamp There has been interest in the DNA polymerase sliding clamp as an antibacterial target for the last 15 years. Sliding...
- Targeting Lipoprotein-Targeting Multidrug-resistant Gram-negative bacteria are a particular problem in both hospital and community settings and treatment is rendered more difficult by...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Monday, November 10th, 2008 at 9:42 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)